Company Filing History:
1 out of 444 
1 out of 4,948 
1 out of 2 Years Active: 2011-2023
Title: **Stefan Endres: Innovator in Bispecific Antibody Molecules and Tumor Therapy**
Introduction
Stefan Endres is an accomplished inventor based in Munich, Germany, known for his significant contributions to the field of biomedicine. With an impressive portfolio of six patents, he has focused his research on innovations that enhance cancer treatment through novel antibody technologies.
Latest Patents
Among his latest patents, the invention titled "Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine" stands out. This patent describes bispecific (monoclonal) antibody molecules that possess a first binding domain capable of targeting an antigen on CD8+ T-cells which does not naturally occur on these cells. Coupled with a second binding domain that targets a tumor-specific antigen, this invention aims to improve therapeutic outcomes using transduced CD8+ T-cells manipulated to express antigens or T-cell receptors absent in their natural state.
Another notable patent is focused on "CXCR6-transduced T cells for targeted tumor therapy." This invention relates to transduced T cells, including CD8+ and CD4+ T cells, designed to treat conditions associated with CXCL16 overexpression. It encompasses innovative nucleic acid sequences and vectors for T-cell transduction, highlighting the use of these engineered cells in treating specific diseases, representing a groundbreaking advancement in targeted therapeutics.
Career Highlights
Stefan Endres has worked with prominent organizations such as Alnylam Pharmaceuticals, where his research has propelled advancements in therapeutic solutions. His work has not only contributed to scientific knowledge but has also paved the way for potential clinical applications that can significantly impact patient care.
Collaborations
In the course of his career, Endres has collaborated with esteemed colleagues, including Sebastian Kobold and Christian Klein. These collaborations have facilitated exchanges of ideas and innovations, enhancing the development of new methodologies in their shared field of study.
Conclusion
Stefan Endres's innovative spirit and dedication to advancing biomedical research have positioned him as a leader in his domain. His work on bispecific antibody molecules and CXCR6-transduced T cells represents promising avenues for improved cancer therapies. As he continues to innovate, the impact of his contributions on the future of medicine is anticipated to be significant.